JP2013529080A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529080A5 JP2013529080A5 JP2013510643A JP2013510643A JP2013529080A5 JP 2013529080 A5 JP2013529080 A5 JP 2013529080A5 JP 2013510643 A JP2013510643 A JP 2013510643A JP 2013510643 A JP2013510643 A JP 2013510643A JP 2013529080 A5 JP2013529080 A5 JP 2013529080A5
- Authority
- JP
- Japan
- Prior art keywords
- dom7h
- seq
- variant
- variable domain
- single variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035772 mutation Effects 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 8
- 108060003951 Immunoglobulin Proteins 0.000 claims 8
- 102000018358 immunoglobulin Human genes 0.000 claims 8
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- -1 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34651910P | 2010-05-20 | 2010-05-20 | |
| US61/346,519 | 2010-05-20 | ||
| PCT/EP2011/058298 WO2011144751A1 (en) | 2010-05-20 | 2011-05-20 | Improved anti-serum albumin binding variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013529080A JP2013529080A (ja) | 2013-07-18 |
| JP2013529080A5 true JP2013529080A5 (enExample) | 2014-07-03 |
Family
ID=44352234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510643A Pending JP2013529080A (ja) | 2010-05-20 | 2011-05-20 | 改良された抗血清アルブミン結合変異体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9040668B2 (enExample) |
| EP (1) | EP2571900A1 (enExample) |
| JP (1) | JP2013529080A (enExample) |
| KR (1) | KR20130109977A (enExample) |
| CN (1) | CN103003303A (enExample) |
| AU (1) | AU2011254559B2 (enExample) |
| BR (1) | BR112012029280A2 (enExample) |
| CA (1) | CA2799633A1 (enExample) |
| EA (1) | EA201291009A1 (enExample) |
| IL (1) | IL222802A0 (enExample) |
| MX (1) | MX2012013406A (enExample) |
| SG (1) | SG185437A1 (enExample) |
| WO (1) | WO2011144751A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| HUE057241T2 (hu) * | 2015-11-13 | 2022-04-28 | Ablynx Nv | Javított, szérumalbumint kötõ immunoglobulin variábilis domének |
| CN115837014A (zh) | 2016-05-18 | 2023-03-24 | 摩登纳特斯有限公司 | 编码松弛素的多核苷酸 |
| IL322519A (en) | 2023-02-17 | 2025-10-01 | Ablynx Nv | Polypeptides that bind to the neonatal fc receptor |
| WO2025021183A1 (zh) * | 2023-07-27 | 2025-01-30 | 上海复宏汉霖生物医药有限公司 | 编码促肾上腺皮质激素的多核苷酸及其相关组合物和方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| CN1678634A (zh) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| ATE479760T1 (de) | 2004-03-24 | 2010-09-15 | Domantis Ltd | Universelles signalpeptid gas1 |
| US8921528B2 (en) | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
| JP5185624B2 (ja) | 2004-12-02 | 2013-04-17 | ドマンティス リミテッド | 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体 |
| US20100047171A1 (en) | 2006-01-24 | 2010-02-25 | Roland Beckmann | Fusion Proteins That Contain Natural Junctions |
| CA2688434A1 (en) * | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
| CA2683801A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| TW200944231A (en) | 2007-11-30 | 2009-11-01 | Glaxo Group Ltd | Antigen-binding constructs |
| MX2011008799A (es) * | 2009-02-19 | 2011-09-27 | Glaxo Group Ltd | Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados. |
| CN105061593B (zh) * | 2009-02-19 | 2018-08-03 | 葛兰素集团有限公司 | 改良的抗血清清蛋白结合变体 |
| AR075505A1 (es) * | 2009-02-19 | 2011-04-06 | Glaxo Group Ltd | Variantes de union a anti- albumina de suero mejoradas |
| US8779103B2 (en) | 2009-03-27 | 2014-07-15 | Glaxo Group Limited | Drug fusions and conjugates |
| JP2012532619A (ja) | 2009-07-16 | 2012-12-20 | グラクソ グループ リミテッド | Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法 |
| KR20120092611A (ko) * | 2009-09-30 | 2012-08-21 | 글락소 그룹 리미티드 | 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트 |
-
2011
- 2011-05-20 SG SG2012081683A patent/SG185437A1/en unknown
- 2011-05-20 EA EA201291009A patent/EA201291009A1/ru unknown
- 2011-05-20 CA CA2799633A patent/CA2799633A1/en not_active Abandoned
- 2011-05-20 WO PCT/EP2011/058298 patent/WO2011144751A1/en not_active Ceased
- 2011-05-20 MX MX2012013406A patent/MX2012013406A/es not_active Application Discontinuation
- 2011-05-20 BR BR112012029280A patent/BR112012029280A2/pt not_active IP Right Cessation
- 2011-05-20 EP EP11720310A patent/EP2571900A1/en not_active Withdrawn
- 2011-05-20 KR KR1020127033268A patent/KR20130109977A/ko not_active Withdrawn
- 2011-05-20 AU AU2011254559A patent/AU2011254559B2/en not_active Ceased
- 2011-05-20 CN CN2011800351661A patent/CN103003303A/zh active Pending
- 2011-05-20 JP JP2013510643A patent/JP2013529080A/ja active Pending
- 2011-05-20 US US13/698,794 patent/US9040668B2/en not_active Expired - Fee Related
-
2012
- 2012-11-01 IL IL222802A patent/IL222802A0/en unknown
-
2015
- 2015-04-21 US US14/691,913 patent/US20150284454A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7840836B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| CN110049997B (zh) | 改进的血清白蛋白结合免疫球蛋白单可变结构域 | |
| CN103619878B (zh) | 结合血清白蛋白的蛋白 | |
| JP2009545319A5 (enExample) | ||
| JP2013538566A5 (enExample) | ||
| JP2017527272A5 (enExample) | ||
| JP2014513953A5 (enExample) | ||
| IL267897B2 (en) | Improved serum albumin binders | |
| JP2010502183A5 (enExample) | ||
| JP2013518853A (ja) | 血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド | |
| JP2017500018A5 (enExample) | ||
| CN108473564A (zh) | 改进的血清白蛋白结合剂 | |
| CN101611056A (zh) | 能够结合于血清蛋白的肽 | |
| JP2018526989A5 (enExample) | ||
| JP2009539349A5 (enExample) | ||
| JP2018113988A (ja) | ＩＬ−１βへの結合メンバー | |
| JP2020521458A5 (enExample) | ||
| JP2010535032A5 (enExample) | ||
| JP2015506945A5 (enExample) | ||
| EA034854B1 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| JP2018519803A5 (enExample) | ||
| JP2013543384A5 (enExample) | ||
| CN101646689A (zh) | 具有长半衰期的血清清蛋白结合蛋白 | |
| JP2018512124A5 (enExample) | ||
| JP2018535972A5 (enExample) |